Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary

Quotient Limited (NASDAQ: QTNT), a diagnostics company based in Switzerland, announced its participation in the BTIG Virtual MedTech Conference on February 18, 2021. The company has over 30 years of experience in transfusion diagnostics and offers the MosaiQ platform, a fully automated testing solution designed to enhance laboratory efficiencies and clinical practices. Additionally, Quotient developed the MosaiQ COVID-19 Antibody Microarray, which has received FDA Emergency Use Authorization and CE marking, contributing to the global fight against COVID-19.

Positive

• Participation in the BTIG Virtual MedTech Conference may enhance visibility and attract potential investors.
• MosaiQ platform offers a fully automated solution expected to increase efficiency and reduce costs for laboratories.
• The MosaiQ COVID-19 Antibody Microarray has received FDA Emergency Use Authorization, expanding its market potential.

Negative

• None.

JERSEY, Channel Islands, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18.

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

CONTACT: Peter Buhler, Chief Financial Officer – IR@quotientbd.com; +41 22 545 52 26

FAQ

When is Quotient Limited participating in the BTIG Virtual MedTech Conference?

Quotient Limited will participate in the BTIG Virtual MedTech Conference on February 18, 2021.

What is the MosaiQ platform developed by Quotient Limited?

The MosaiQ platform is a fully automated testing solution that allows for multiple tests across different modalities, aimed at increasing laboratory efficiency.

What is the significance of the MosaiQ COVID-19 Antibody Microarray?

The MosaiQ COVID-19 Antibody Microarray has been granted FDA Emergency Use Authorization and CE marking, contributing to global COVID-19 response efforts.

What experience does Quotient Limited have in the diagnostics field?

Quotient Limited has over 30 years of experience in transfusion diagnostics.